Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults
Edward J Carra b✉, Hermaleigh Townsleya b c, Mary Wua b d, Katalin Andrea Wilkinsona b e, Philip S. Hobsona b, Dina Levia b, Sina Namjoua b, Harriet V Mearsa b, Agnieszka Hobbsa b d, Martina Ragnoa b d, Lou S Hermana b d,
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
ABSTRACT Heterogeneity in SARS-CoV-2 vaccine responses is not understood. Here, we identify four patterns of live-virus neutralizing antibody responses: individuals with hybrid immunity (with confirmed prior infection); rare individuals with low responses (paucity of S1-binding antibodies); and surprisingly, two further groups with distinct serological repertoires. One group – broad responders – neutralize a range of SARS-CoV-2 variants, whereas the other – narrow responders – neutralize fewer, less divergent variants. This heterogeneity does not correlate with Ancestral S1-binding antibody, rather the quality of the serological response. Furthermore, IgD low CD27 - CD137 + B cells and CCR6 + CD4 + T cells are enriched in broad responders before dose 3. Notably, broad responders have significantly longer infection-free time after their third dose. Understanding the control and persistence of these serological profiles could allow personalized approaches to enhance serological breadth after vaccination.
TL;DRFour patterns of live-virus neutralizing antibody responses are identified: individuals with hybrid immunity (with confirmed prior infection); rare individuals with low responses (paucity of S1-binding antibodies); and surprisingly, two further groups with distinct serological repertoires. (Semantic Scholar)